Bioprocessing & Manufacturing

 

 

With new vaccine formulations and technology platforms, vaccine developers need to have the right processes in place to manufacture them during clinical trials and at commercial scale. Use this opportunity to meet with the manufacture and bioprocessing leads who need services for all of the latest manufacturing challenges, from formulating and manufacturing adjuvants, mRNA platforms, VLPs and viral vectors, to technology transfer and continuous manufacturing.

 

2018 AGENDA

 

Bioprocess & Manufacture, Wednesday 4 April 2018

Bioprocess & Manufacture
09:00

Chair’s opening remarks

Vaccine Bioprocessing

Dr Don Gerson
Bioprocess & Manufacture
09:10

What can we learn from mAB bioprocessing to vaccines to make more vaccines? From R&D to full scale manufacturing and worldwide distribution

  • The transition from lab to manufacturing and large-scale production of low cost vaccines globally
Dr Ahd Hamidi
Bioprocess & Manufacture
09:40

How innovative process development allows for a novel cost-effective rotavirus vaccine

Bioprocess & Manufacture
09:55

Overview of cell culture & new expression systems improving vaccine bioprocessing

Bioprocess & Manufacture
10:10

New approaches for analytical characterization: Can in vitro potency approaches be used to replace animal models?

10:40

Networking coffee break

Dr Hari Pujar
Bioprocess & Manufacture
11:40

Comparing traditional vaccine manufacturing to mRNA vaccine manufacturing

Bioprocess & Manufacture
12:10

New VLP production techniques: Challenges and opportunities

Vaccine Production and Delivery Systems

Dr Max Søgaard
Bioprocess & Manufacture
12:25

ExpreS2 – an insect cell based vaccine production system suitable for difficult-to-express proteins

Wendy Saffell-Clemmer
Bioprocess & Manufacture
12:40

Analytical characterization of aluminum adsorbed vaccines: Stability indicating methods for product release

  • What general guidance is there on release and stability test methods for aluminum adsorbed vaccines?  
  • Understanding of the antigen stability following adsorption
  • Reviewing potential release tests and proposing a panel of stability indicating tests for aluminum adsorbed vaccines
1:10

Networking Lunch & Poster Session

Darin Zehrung
Bioprocess & Manufacture
2:40

Review of the current alternative vaccine delivery methods and how their effectiveness is assessed

  • The advantages and progression of up taking alternative delivery systems and packaging
  • The logistical challenges to consider for developing countries
  • How to make new technologies applicable and build a stronger business case to be used
  • Total system effectiveness: Cost modelling of delivery systems
Michael A. Schrader
Bioprocess & Manufacture
3:10

Creating the next generation of vaccines and immunotherapies by mimicking an infection to enhance the immune response

  • Illustrating how the delivery of sustained release vaccine depots via microneedle patch improves immunogenicity
  • Logistical conquest in easy administration, shelf life stability and only minutes of wear time
  • Current progress with an in-house influenza vaccine and partnered programs to advance formulation for optimal patient uptake
Dr Gregory Glenn
Bioprocess & Manufacture
3:25

Solutions for intradermal administration & clinical experience with the MicronJet600R

Bioprocess & Manufacture
3:40

Dry powder vaccine stabilization and delivery by spray drying

  • Methods and considerations for Spray dried macromolecules
  • Different Delivery Routes and their application to spray drying
  • Enteric Capsules for oral delivery and rapid pre-clinical development
  • Case Studies
4:10

Networking coffee break

Bioreactor needs for the developed & developing world

Peter Khoury
Bioprocess & Manufacture
4:40

Vaccine self-sufficiency and responding to pandemic outbreaks from small to large scale

  • Understanding in securing strains, safety,  regulatory hurdles and manufacturing hurdles
  • Considering the logistics of distribution
Bioprocess & Manufacture
5:10

A platform approach for viral vaccine manufacturing

  • Our platform approach for the manufacturing of viral vaccines
  • How technological developments help to set-up a robust and scalable process using single use technologies
Dr Yan-ping Yang
Bioprocess & Manufacture
5:40

Continuous Process for Vaccine Manufacturing: Challenges and opportunities

  • Experiences & lessons learned from the industry on continuous processing
  • Disposable technology & continuous technology: a powerful combination
  • Rapid technology advancement for key enablers to support continuous processing
  • FDA Fully on Board with the Concept of continuous processing
6:10

Chair’s closing remarks and close of congress day 2

6:15

Networking Drinks & Party

last published: 10/Nov/17 15:15

Bioprocess & Manufacture, Thursday 5 April 2018

Enabling Technologies from Discovery to Market

Prof Fikri Avci
Bioprocess & Manufacture
09:10

Understanding how vaccines elicit immune responses

Dr Frederick Porter
Bioprocess & Manufacture
09:40

Enabling translation of vaccine discovery into clinical candidates in academia

Dr Fiona Lin
Bioprocess & Manufacture
10:10

Designing vaccines focusing on critical quality attributes and analytical strategies

10:40

Networking coffee break

Dr Viliam Pavliak
Bioprocess & Manufacture
11:30

Developing vaccines for developing countries – A case study on Typhoid conjugate vaccine

12:30

Networking Lunch & Poster Session

AFTERNOON PLENARY OF CONGRESS

last published: 10/Nov/17 15:15

 

DOWNLOAD DRAFT AGENDA

Get Involved At World Vaccine Congress Washington

 

To Sponsor Or Exhibit

 

Marc Rhys-Evans
marc.rhys-evans@terrapinn.com
+44 20 7827 5945

 

 

 

To Register

 

Tayyab Abbasi
tayyab.abbasi@terrapinn.com
+44 20 7092 1210

 

 

 

Press Relations

 

Karina Kusova
karina.kusova@terrapinn.com
+44 20 7092 1071